Literature DB >> 30054585

Resolution of inflammation-induced depression requires T lymphocytes and endogenous brain interleukin-10 signaling.

Geoffroy Laumet1, Jules Daniel Edralin1, Angie Chi-An Chiang1, Robert Dantzer1, Cobi J Heijnen1, Annemieke Kavelaars2.   

Abstract

In humans, depression is often associated with low-grade inflammation, activation of the tryptophan/kynurenine pathway, and mild lymphopenia. Preclinical research confirms that inflammation induces depression-like behavior through activation of the tryptophan/kynurenine pathway. However, the mechanisms governing recovery from depression are unknown. Understanding the pathways leading to resolution of depression will likely lead to identification of novel targets for treatment. We investigated the contribution of T lymphocytes to the resolution of lipopolysaccharide-induced depression-like behavior. Duration of depression-like behavior was markedly prolonged in mice without mature T or B lymphocytes (Rag1-/- mice). This prolonged depression-like behavior was associated with persistent upregulation of the tryptophan-metabolizing enzyme indoleamine-2,3-dioxygenase (Ido)1 in the prefrontal cortex (PFC). Reconstitution of Rag1-/- mice with T lymphocytes normalized resolution of depression-like behavior and expression of Ido1 in the PFC. During resolution of inflammation-induced depression-like behavior, T lymphocytes accumulated in the meninges and were required for induction of interleukin (IL)-10 in the meninges and the PFC. Inhibition of IL-10 signaling by nasal administration of neutralizing anti-IL-10 antibody to WT mice led to persistent upregulation of Ido1 in the PFC and prolonged depression-like behavior. Conversely, nasal administration of recombinant IL-10 in Rag1-/- mice normalized Ido1 expression and resolution of depression-like behavior. In conclusion, the present data show for the first time that resolution of inflammation-induced depression is an active process requiring T lymphocytes acting via an IL-10-dependent pathway to decrease Ido1 expression in the brain. We propose that targeting the T lymphocyte/IL-10 resolution pathway could represent a novel approach to promote recovery from major depressive disorder.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30054585      PMCID: PMC6224384          DOI: 10.1038/s41386-018-0154-1

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  57 in total

1.  Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

Authors:  L Capuron; A Ravaud
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

2.  The burden of depression.

Authors: 
Journal:  Nature       Date:  2014-11-13       Impact factor: 49.962

Review 3.  The role of inflammation in depression: from evolutionary imperative to modern treatment target.

Authors:  Andrew H Miller; Charles L Raison
Journal:  Nat Rev Immunol       Date:  2016-01       Impact factor: 53.106

4.  Monocytes/Macrophages control resolution of transient inflammatory pain.

Authors:  Hanneke L D M Willemen; Niels Eijkelkamp; Anibal Garza Carbajal; Huijing Wang; Matthias Mack; Jitske Zijlstra; Cobi J Heijnen; Annemieke Kavelaars
Journal:  J Pain       Date:  2014-05       Impact factor: 5.820

5.  Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression.

Authors:  Hyangin Kim; Lucy Chen; Grewo Lim; Backil Sung; Shuxing Wang; Michael F McCabe; Gabriel Rusanescu; Liling Yang; Yinghong Tian; Jianren Mao
Journal:  J Clin Invest       Date:  2012-07-02       Impact factor: 14.808

6.  Psychiatric complications of long-term interferon alfa therapy.

Authors:  P F Renault; J H Hoofnagle; Y Park; K D Mullen; M Peters; D B Jones; V Rustgi; E A Jones
Journal:  Arch Intern Med       Date:  1987-09

7.  A dynamic course of T cell defects in individuals at risk for mood disorders.

Authors:  G Snijders; C Schiweck; E Mesman; L Grosse; H De Wit; W A Nolen; H A Drexhage; M H J Hillegers
Journal:  Brain Behav Immun       Date:  2016-05-12       Impact factor: 7.217

8.  Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation.

Authors:  Chiara Berlato; Marco A Cassatella; Ichiko Kinjyo; Luana Gatto; Akihiko Yoshimura; Flavia Bazzoni
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

9.  IL-10 within the CNS is necessary for CD4+ T cells to mediate neuroprotection.

Authors:  Junping Xin; Derek A Wainwright; Nichole A Mesnard; Craig J Serpe; Virginia M Sanders; Kathryn J Jones
Journal:  Brain Behav Immun       Date:  2010-08-17       Impact factor: 7.217

10.  Replicable and Coupled Changes in Innate and Adaptive Immune Gene Expression in Two Case-Control Studies of Blood Microarrays in Major Depressive Disorder.

Authors:  Gwenaël G R Leday; Petra E Vértes; Sylvia Richardson; Jonathan R Greene; Tim Regan; Shahid Khan; Robbie Henderson; Tom C Freeman; Carmine M Pariante; Neil A Harrison; V Hugh Perry; Wayne C Drevets; Gayle M Wittenberg; Edward T Bullmore
Journal:  Biol Psychiatry       Date:  2017-07-06       Impact factor: 13.382

View more
  21 in total

Review 1.  Targeting the Adaptive Immune System in Depression: Focus on T Helper 17 Cells.

Authors:  Eléonore Beurel; Eva M Medina-Rodriguez; Richard S Jope
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

2.  Nasal administration of mesenchymal stem cells reverses chemotherapy-induced peripheral neuropathy in mice.

Authors:  Nabila Boukelmoune; Geoffroy Laumet; Yongfu Tang; Jiacheng Ma; Itee Mahant; Susmita K Singh; Cora Nijboer; Manon Benders; Annemieke Kavelaars; Cobi J Heijnen
Journal:  Brain Behav Immun       Date:  2020-12-11       Impact factor: 7.217

Review 3.  T Cells as Guardians of Pain Resolution.

Authors:  Annemieke Kavelaars; Cobi J Heijnen
Journal:  Trends Mol Med       Date:  2021-01-08       Impact factor: 11.951

4.  Cisplatin educates CD8+ T cells to prevent and resolve chemotherapy-induced peripheral neuropathy in mice.

Authors:  Geoffroy Laumet; Jules D Edralin; Robert Dantzer; Cobi J Heijnen; Annemieke Kavelaars
Journal:  Pain       Date:  2019-06       Impact factor: 7.926

5.  A Novel Syngeneic Immunocompetent Mouse Model of Head and Neck Cancer Pain Independent of Interleukin-1 Signaling.

Authors:  Matthew J Heussner; Joseph K Folger; Christina Dias; Noura Massri; Albert Dahdah; Paola D Vermeer; Geoffroy Laumet
Journal:  Anesth Analg       Date:  2021-04-01       Impact factor: 6.627

6.  Interleukin-10 resolves pain hypersensitivity induced by cisplatin by reversing sensory neuron hyperexcitability.

Authors:  Geoffroy Laumet; Alexis Bavencoffe; Jules D Edralin; Xiao-Jiao Huo; Edgar T Walters; Robert Dantzer; Cobi J Heijnen; Annemieke Kavelaars
Journal:  Pain       Date:  2020-10       Impact factor: 7.926

7.  Serum Markers of Inflammation Mediate the Positive Association Between Neuroticism and Depression.

Authors:  Frank M Schmidt; Christian Sander; Juliane Minkwitz; Roland Mergl; Bethan Dalton; Lesca M Holdt; Daniel Teupser; Ulrich Hegerl; Hubertus Himmerich
Journal:  Front Psychiatry       Date:  2018-11-20       Impact factor: 4.157

8.  Psychological symptoms and salivary inflammatory biomarkers in patients with dentofacial deformities: a case-control study.

Authors:  Maria C C Volkweis; Gabriela W Neculqueo; Raquel D S Freitas; Ana P A Dagnino; Guilherme G Fritscher; Tatiana Q Irigaray; Maria M Campos
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379

Review 9.  T-Cell Mediated Inflammation in Postmenopausal Osteoporosis.

Authors:  Di Wu; Anna Cline-Smith; Elena Shashkova; Ajit Perla; Aditya Katyal; Rajeev Aurora
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

Review 10.  α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis.

Authors:  Laura M Butkovich; Madelyn C Houser; Malú G Tansey
Journal:  Front Neurosci       Date:  2018-09-11       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.